ALNY Q3 2025 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.2B+149.3% YoY

Gross Profit

$1.1B84.2% margin

Operating Income

$368M29.5% margin

Net Income

$251M20.1% margin

EPS (Diluted)

$1.84

QoQ Revenue Growth

+61.4%

Cash Flow

Operating Cash Flow

$325M

Free Cash Flow

$313M

Stock-Based Comp.

$108M

Balance Sheet

Total Assets

$4.9B

Total Liabilities

$4.6B

Stockholders' Equity

$234M

Cash & Equivalents

$1.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.2B	$501M	+149.3%
Gross Profit	$1.1B	$415M	+153.4%
Operating Income	$368M	-$77M	+578.5%
Net Income	$251M	-$112M	+325.0%